Inhibitor Therapeutics (INTI) News Today $0.06 +0.01 (+20.00%) As of 04/1/2025 01:04 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Drop in Short InterestMarch 27, 2025 | americanbankingnews.comPeptide screening reveals irreversible inhibitors for cancer's 'undruggable' cJun proteinMarch 21, 2025 | msn.comIndaptus Therapeutics initiates Phase 1 study of Decoy20March 19, 2025 | markets.businessinsider.comNext-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical TestingMarch 12, 2025 | markets.businessinsider.comJanus Kinase (JAK) Inhibitor Pipeline Market Insights Report 2025: Comprehensive Review of 50+ Companies and Respective 55+ DrugsMarch 4, 2025 | finance.yahoo.comHDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsightFebruary 11, 2025 | theglobeandmail.comAceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025February 8, 2025 | businesswire.comVera Therapeutics acquires global rights to next-gen dual BAFF/APRIL inhibitorJanuary 13, 2025 | markets.businessinsider.comEli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In CashJanuary 13, 2025 | markets.businessinsider.comEnzyme Inhibitor Market to Reach US$ 5.9 Bn by 2034 Amid Rising Demand for Cardiovascular and Oncology Therapies - Transparency Market Research, Inc.December 16, 2024 | finance.yahoo.comComplement Inhibitor Therapeutics Pipeline Developments Research Report 2024December 5, 2024 | globenewswire.comPathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid CancersNovember 21, 2024 | finance.yahoo.comComplement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsightOctober 28, 2024 | globenewswire.comOptimism Surrounds Indaptus Therapeutics’ Decoy20 Amid Strategic Partnerships and Promising Preclinical DataOctober 23, 2024 | markets.businessinsider.comINTEGRA Biosciences’ pipettes help progress small molecule inhibitors from discovery to clinical trialsOctober 23, 2024 | msn.comIambic Therapeutics Named to the Endpoints 11 List of Biotech's Most Promising StartupsSeptember 27, 2024 | tmcnet.comDeepCure to Present In Vivo Efficacy and Safety Data of BRD4 (BD2) Inhibitor DC-9476 for Macrophage Activation Syndrome at EMBO ConferenceSeptember 17, 2024 | finance.yahoo.comInternational Industries Ltd (INTI)August 31, 2024 | uk.investing.comInhibitor Therapeutics, Inc. Provides Update on its Clinical Development PlanAugust 22, 2024 | globenewswire.comJanus Kinase (JAK) Inhibitor Therapeutic Report 2024: Strategic Evaluation of Over 50 Companies and 55+ Pipeline DrugsAugust 15, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comOncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 9, 2024 | markets.businessinsider.comNew dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistanceJuly 30, 2024 | msn.comPreview: Actuate Therapeutics, Inc Set To IPO TomorrowJuly 25, 2024 | benzinga.comActuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To KnowJuly 24, 2024 | benzinga.comActuate Therapeutics Seeks IPO For Promising Pancreatic Cancer DrugsMay 29, 2024 | seekingalpha.comNimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual MeetingMay 23, 2024 | businesswire.comMC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion StrategyMay 13, 2024 | tmcnet.comGTHX G1 Therapeutics, Inc.April 30, 2024 | seekingalpha.comHDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsightApril 24, 2024 | finance.yahoo.comEGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsightApril 22, 2024 | finance.yahoo.comCyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth ProspectsApril 15, 2024 | finance.yahoo.comSaruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialApril 8, 2024 | msn.comWatchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection ApplicationsApril 3, 2024 | finance.yahoo.comJanus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future OpportunitiesMarch 14, 2024 | finance.yahoo.comExploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034March 14, 2024 | finance.yahoo.comiTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchJanuary 10, 2024 | seekingalpha.comVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of VitiligoJanuary 10, 2024 | tmcnet.comIntroducing Inhibitor Therapeutics, Inc. New Scientific Advisory BoardDecember 19, 2023 | finance.yahoo.comInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins UniversityDecember 13, 2023 | finance.yahoo.comInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProDecember 4, 2023 | tmcnet.comInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNovember 14, 2023 | markets.businessinsider.comCardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023November 7, 2023 | finance.yahoo.comAntiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer TherapeuticsOctober 16, 2023 | businesswire.comNykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical CancerSeptember 5, 2023 | benzinga.comTrueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 18, 2023 | finanznachrichten.deTrueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810May 18, 2023 | businesswire.comCorrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030May 17, 2023 | marketwatch.comWax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030May 17, 2023 | marketwatch.comInhibitor Therapeutics Inc.April 20, 2023 | wsj.com Remove Ads Get Inhibitor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter. Email Address INTI Media Mentions By Week INTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INTI News Sentiment▼0.560.57▲Average Medical News Sentiment INTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INTI Articles This Week▼20▲INTI Articles Average Week Remove Ads Get Inhibitor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Atara Biotherapeutics News Today Verrica Pharmaceuticals News Today Lantern Pharma News Today Dyadic International News Today SCYNEXIS News Today Medicus Pharma News Today Eliem Therapeutics News Today KALA BIO News Today ALX Oncology News Today Xilio Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:INTI) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INTI Stock Free INTI Stock Alerts